{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,8]],"date-time":"2026-02-08T07:44:39Z","timestamp":1770536679474,"version":"3.49.0"},"reference-count":32,"publisher":"Scientific Scholar","content-domain":{"domain":["ijdvl.com"],"crossmark-restriction":true},"short-container-title":["IJDVL"],"DOI":"10.25259\/ijdvl_191_20","type":"journal-article","created":{"date-parts":[[2021,1,29]],"date-time":"2021-01-29T07:32:12Z","timestamp":1611905532000},"page":"131-134","update-policy":"https:\/\/doi.org\/10.25259\/crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Ozenoxacin: A novel topical antibiotic"],"prefix":"10.25259","volume":"87","author":[{"given":"Parvathy","family":"Santhosh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mithun Harold","family":"Thomas","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Government Medical College, Kozhikode, Kerala, India"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"10894","published-online":{"date-parts":[[2021,2,5]]},"reference":[{"key":"10.25259\/IJDVL_191_20\/ref-1","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1046\/j.1365-4362.2003.01647.x","article-title":"Impetigo: An update","volume":"42","author":"Brown","year":"2003","journal-title":"Int J Dermatol"},{"key":"10.25259\/IJDVL_191_20\/ref-2","first-page":"252","volume-title":"British National Formulary","author":"British Medical Association & Royal Pharmaceutical Society of Great Britain","year":"2001"},{"key":"10.25259\/IJDVL_191_20\/ref-3","first-page":"480","article-title":"A systematic review and meta-analysis of treatments for impetigo","volume":"53","author":"George","year":"2003","journal-title":"Br J Gen Pract"},{"key":"10.25259\/IJDVL_191_20\/ref-4","doi-asserted-by":"publisher","first-page":"77","DOI":"10.4103\/0378-6323.58693","article-title":"Retapamulin: A novel topical antibiotic","volume":"76","author":"Nagabushan","year":"2010","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"10.25259\/IJDVL_191_20\/ref-6","doi-asserted-by":"publisher","first-page":"a025437","DOI":"10.1101\/cshperspect.a025437","article-title":"Fusidic acid: A bacterial elongation factor inhibitor for the oral treatment of acute and chronic staphylococcal infections","volume":"6","author":"Fernandes","year":"2016","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10.25259\/IJDVL_191_20\/ref-7","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1007\/s100960050306","article-title":"Molecular characterization and transfer among Staphylococcus strains of a plasmid conferring high-level resistance to mupirocin","volume":"18","author":"Bastos","year":"1999","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.25259\/IJDVL_191_20\/ref-8","doi-asserted-by":"publisher","first-page":"2681","DOI":"10.1093\/jac\/dkv169","article-title":"Mupirocin resistance: Clinical implications and potential alternatives for the eradication of MRSA","volume":"70","author":"Poovelikunnel","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"10.25259\/IJDVL_191_20\/ref-9","doi-asserted-by":"publisher","first-page":"2279","DOI":"10.1128\/JCM.01834-08","article-title":"Mupirocin resistance among methicillin-resistant Staphylococcus aureus-colonized patients at admission to a tertiary care medical center","volume":"47","author":"Babu","year":"2009","journal-title":"J Clin Microbiol"},{"key":"10.25259\/IJDVL_191_20\/ref-11","doi-asserted-by":"publisher","first-page":"259","DOI":"10.2174\/1570163815666180502165014","article-title":"Ozenoxacin: A novel drug discovery for the treatment of impetigo","volume":"16","author":"Sahu","year":"2019","journal-title":"Curr Drug Discov Technol"},{"key":"10.25259\/IJDVL_191_20\/ref-12","doi-asserted-by":"publisher","first-page":"6389","DOI":"10.1128\/AAC.01509-13","article-title":"In vitro activity of ozenoxacin against quinolone-susceptible and quinolone-resistant Gram-positive bacteria","volume":"57","author":"L\u00f3pez","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.25259\/IJDVL_191_20\/ref-13","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1111\/j.1751-7915.2008.00063.x","article-title":"Mechanism of action of and resistance to quinolones","volume":"2","author":"F\u00e0brega","year":"2009","journal-title":"Microb Biotechnol"},{"key":"10.25259\/IJDVL_191_20\/ref-14","doi-asserted-by":"publisher","first-page":"9611","DOI":"10.1093\/nar\/gkx649","article-title":"Activities of gyrase and topoisomerase IV on positively supercoiled DNA","volume":"45","author":"Ashley","year":"2017","journal-title":"Nucleic Acids Res"},{"key":"10.25259\/IJDVL_191_20\/ref-15","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1128\/.61.3.377-392.1997","article-title":"DNA gyrase, topoisomerase IV, and the 4-quinolones","volume":"61","author":"Drlica","year":"1997","journal-title":"Microbiol Mol Biol Rev"},{"key":"10.25259\/IJDVL_191_20\/ref-16","first-page":"11","article-title":"DNA topoisomerase: The key enzyme that regulates DNA super structure","volume":"61","author":"Kato","year":"1998","journal-title":"Nagoya J Med Sci"},{"key":"10.25259\/IJDVL_191_20\/ref-17","doi-asserted-by":"publisher","first-page":"3544","DOI":"10.1128\/AAC.45.12.3544-3547.2001","article-title":"Target preference of 15 quinolones against Staphylococcus aureus, based on antibacterial activities and target inhibition","volume":"45","author":"Takei","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"10.25259\/IJDVL_191_20\/ref-18","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1080\/14787210.2019.1573671","article-title":"Ozenoxacin: A review of preclinical and clinical efficacy","volume":"17","author":"Vila","year":"2019","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.25259\/IJDVL_191_20\/ref-19","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1177\/1060028018786510","article-title":"Ozenoxacin: A novel topical quinolone for impetigo","volume":"52","author":"Wren","year":"2018","journal-title":"Ann Pharmacother"},{"key":"10.25259\/IJDVL_191_20\/ref-20","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1093\/jac\/49.3.455","article-title":"In vitro and in vivo antibacterial activity of T-3912, a novel non-fluorinated topical quinolone","volume":"49","author":"Yamakawa","year":"2002","journal-title":"J Antimicrob Chemother"},{"key":"10.25259\/IJDVL_191_20\/ref-21","doi-asserted-by":"publisher","first-page":"3","DOI":"10.2217\/fmb-2017-0289","article-title":"Comparative in vitro antibacterial activity of ozenoxacin against Gram-positive clinical isolates","volume":"13","author":"Canton","year":"2018","journal-title":"Future Microbiol"},{"key":"10.25259\/IJDVL_191_20\/ref-22","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.2217\/fmb.14.78","article-title":"Ozenoxacin 1% cream in the treatment of impetigo: A multicenter, randomized, placebo-and retapamulin-controlled clinical trial","volume":"9","author":"Gropper","year":"2014","journal-title":"Future Microbiol"},{"key":"10.25259\/IJDVL_191_20\/ref-23","doi-asserted-by":"publisher","first-page":"s104","DOI":"10.25251\/skin.1.supp.103","article-title":"A randomized vehicle-controlled trial to assess the efficacy, safety, and tolerability of ozenoxacin 1% cream in 465 patients 2 years and older with impetigo","volume":"1","author":"Albareda","year":"2017","journal-title":"J Cutan Med"},{"key":"10.25259\/IJDVL_191_20\/ref-24","doi-asserted-by":"publisher","first-page":"21","DOI":"10.2217\/fmb-2017-0290","article-title":"Therapeutic efficacy of ozenoxacin in animal models of dermal infection with Staphylococcus aureus","volume":"13","author":"Tarrag\u00f3","year":"2018","journal-title":"Future Microbiol"},{"key":"10.25259\/IJDVL_191_20\/ref-25","first-page":"146","article-title":"Accumulation of ozenoxacin and other quinolones in Gram-positive bacteria","volume":"36","author":"L\u00f3pez Cubillos","year":"2018","journal-title":"Enferm Infecc Microbiol Clin"},{"key":"10.25259\/IJDVL_191_20\/ref-26","article-title":"Ozanex (Ozenoxacin): 1% w\/w Topical Antibiotic Cream [Product Monograph]","year":"2017","journal-title":"Barcelona (ES): Ferrer Internacional, S.A."},{"key":"10.25259\/IJDVL_191_20\/ref-27","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1186\/s12866-015-0572-8","article-title":"Impact of efflux in the development of multidrug resistance phenotypes in Staphylococcus aureus","volume":"15","author":"Santos Costa","year":"2015","journal-title":"BMC Microbiol"},{"key":"10.25259\/IJDVL_191_20\/ref-28","doi-asserted-by":"publisher","first-page":"S11","DOI":"10.2217\/fmb.14.82","article-title":"Systemic bioavailability, safety and tolerability of topical ozenoxacin in healthy adult volunteers","volume":"9","author":"Gropper","year":"2014","journal-title":"Future Microbiol"},{"key":"10.25259\/IJDVL_191_20\/ref-29","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1001\/jamadermatol.2018.1103","article-title":"Efficacy and safety of ozenoxacin cream for treatment of adult and pediatric patients with impetigo: A randomized clinical trial","volume":"154","author":"Rosen","year":"2018","journal-title":"JAMA Dermatol"},{"key":"10.25259\/IJDVL_191_20\/ref-30","article-title":"Clinical Review Report: Ozenoxacin 1% Cream (Ozanex)","author":"Ferrer Internacional S.A","year":"2018"},{"key":"10.25259\/IJDVL_191_20\/ref-31","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1159\/000504536","article-title":"Ozenoxacin, a new effective and safe topical treatment for impetigo in children and adolescents","volume":"236","author":"Torrelo","year":"2020","journal-title":"Dermatology"},{"key":"10.25259\/IJDVL_191_20\/ref-32","doi-asserted-by":"publisher","first-page":"S23","DOI":"10.2217\/fmb.14.84","article-title":"Cumulative irritation, sensitizing potential, phototoxicity and photoallergy of ozenoxacin in healthy adult volunteers","volume":"9","author":"Gropper","year":"2014","journal-title":"Future Microbiol"},{"key":"10.25259\/IJDVL_191_20\/ref-33","doi-asserted-by":"publisher","first-page":"31","DOI":"10.2217\/fmb-2017-0291","article-title":"Studies on articular and general toxicity of orally administered ozenoxacin in juvenile rats and dogs","volume":"13","author":"Gonz\u00e1lez Borroto","year":"2018","journal-title":"Future Microbiol"},{"key":"10.25259\/IJDVL_191_20\/ref-34","doi-asserted-by":"publisher","first-page":"S33","DOI":"10.2217\/fmb.14.85","article-title":"Systemic bioavailability and safety of twice-daily topical ozenoxacin 1% cream in adults and children with impetigo","volume":"9","author":"Gropper","year":"2014","journal-title":"Future Microbiol"}],"container-title":["Indian Journal of Dermatology, Venereology and Leprology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ijdvl.com\/ozenoxacin-a-novel-topical-antibiotic\/","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.ijdvl.com\/ozenoxacin-a-novel-topical-antibiotic\/","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,8]],"date-time":"2021-02-08T21:41:20Z","timestamp":1612820480000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ijdvl.com\/ozenoxacin-a-novel-topical-antibiotic\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,5]]},"references-count":32,"alternative-id":["10.25259\/IJDVL_191_20"],"URL":"https:\/\/doi.org\/10.25259\/ijdvl_191_20","relation":{},"ISSN":["0378-6323"],"issn-type":[{"value":"0378-6323","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,5]]},"article-number":"131"}}